Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.98
-0.1550-7.28%
Volume:2.96M
Turnover:6.00M
Market Cap:73.91M
PE:-1.34
High:2.14
Open:2.13
Low:1.96
Close:2.13
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:0.47
T/O Rate:16.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.65
PE(LYR):-1.47

Loading ...

Aug 12, 2024

Major Issues Report

Form 8-K - Current report
Aug 06, 2024

Major Issues Report

Form 8-K - Current report
Jun 13, 2024

Major Issues Report

Form 8-K - Current report
May 14, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 14, 2024

Major Issues Report

Form 8-K - Current report
Mar 28, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 23, 2024

Major Issues Report

Form 8-K - Current report
Feb 20, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 20, 2024

Major Issues Report

Form 8-K - Current report
Feb 16, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 12, 2024

Major Issues Report

Form 8-K - Current report
Feb 08, 2024

Major Issues Report

Form 8-K - Current report
Feb 06, 2024

Major Issues Report

Form 8-K - Current report
Feb 06, 2024

Correspondence

Form CORRESP - Correspondence
Feb 06, 2024

Correspondence

Form CORRESP - Correspondence
Feb 02, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Feb 02, 2024

Correspondence

Form CORRESP - Correspondence